Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TCR2 THERAPEUTICS INC.TCRR · Entity 94327 | 10% owner | December 18, 2019 | December 20, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TCR2 THERAPEUTICS INC.
Report date December 18, 2019 · Filed December 20, 2019
Jointly reported with Jovan-Embiricos Morana, Globeways Holdings Ltd, Globeways Holdings II Ltd, F2 Capital I 2015 Ltd, F2 Captial I 2017 Ltd, F2 MG Ltd, F2 Bioscience II 2017 Ltd, F2 - TPO Investments LLC, F2 Capital I 2019, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 89,217 |
Reported balance
After 2019-12-18 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2019-12-18 · Sale · Disposed 458 · Balance 89,217 F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 191,309 |
Reported balance
After 2019-12-18 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2019-12-18 · Sale · Disposed 2,433 · Balance 191,309 F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 82,575 |
Reported balance
After 2019-12-19 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2019-12-19 · Sale · Disposed 6,642 · Balance 82,575 F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 155,986 |
Reported balance
After 2019-12-19 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2019-12-19 · Sale · Disposed 35,323 · Balance 155,986 F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 713,723 |
Reported balance
After 2019-12-20 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2019-12-20 · Other · Disposed 586,153 · Balance 713,723 F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners. F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 161,024 |
Reported balance
After 2019-12-20 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2019-12-20 · Other · Disposed 13,847 · Balance 161,024 F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners. F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 361,665 |
Reported balance
Holding disclosure · report date 2019-12-18 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 361,665 F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 432,319 |
Reported balance
Holding disclosure · report date 2019-12-18 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 432,319 F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fund | 330,238 |
Reported balance
Holding disclosure · report date 2019-12-18 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 330,238 F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F2: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F3: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners.
F4: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F5: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners.
F6: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F7: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F8: The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
F9: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | OtherCommon Stock | 13,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 161,024 F5 · kind: Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners. F6 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 20, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | OtherCommon Stock | 586,153 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 713,723 F3 · kind: Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners. F4 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 35,323 | $16.47 | $581,819.26 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 155,986 F2 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 6,642 | $16.47 | $109,403.04 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 82,575 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 2,433 | $17.01 | $41,375.60 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 191,309 F2 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 17:31 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 458 | $17.01 | $7,788.75 |
DisclosureSEC source: 0000899243-19-029791 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 89,217 F1 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 5,516 | $17.31 | $95,489.68 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 12 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,411,656 F6 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,401 | $17.31 | $24,253.27 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 11 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 358,633 F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,835 | $17.31 | $31,766.42 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 10 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 469,464 F4 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 351 | $17.31 | $6,076.30 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 9 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 89,675 F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 683 | $17.31 | $11,823.69 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 8 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 174,871 F2 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 1,535 | $17.31 | $26,573.00 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 7 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 392,765 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 197,343 | $17.94 | $3,539,425.64 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,417,172 F6 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 50,134 | $17.94 | $899,173.34 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 360,034 F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 65,633 | $17.94 | $1,177,154.11 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 471,299 F4 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 12,537 | $17.94 | $224,856.11 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 90,026 F3 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 24,446 | $17.94 | $438,448.79 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 175,554 F2 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| September 20, 2019 Filed Sep 24, 2019 20:27 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | SaleCommon Stock | 54,907 | $17.94 | $984,779.01 |
DisclosureSEC source: 0000899243-19-024208 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 394,300 F1 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionSeries B Preferred Stock · Derivative | 2,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 14 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 403,629 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F7 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionSeries B Preferred Stock · Derivative | 1,750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 13 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 282,540 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F6 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionSeries B Preferred Stock · Derivative | 2,540,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 12 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 410,168 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionSeries B Preferred Stock · Derivative | 1,200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 11 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 193,742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F3 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F4 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionSeries A Preferred Stock · Derivative | 10,000,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · derivative · entry 10 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 0 Underlying: Common Stock · 1,614,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 133,333 | $15.00 | $1,999,995.00 |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 9 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 536,962 F7 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 166,667 | $15.00 | $2,500,005.00 |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 8 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 449,207 F6 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 166,667 | $15.00 | $2,500,005.00 |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 7 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 166,667 F9 · ownership.nature: The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 200,000 | $15.00 | $3,000,000.00 |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 6 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 200,000 F8 · ownership.nature: The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionCommon Stock | 403,629 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 5 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 403,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F7 · ownership.nature: The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionCommon Stock | 282,540 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 4 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 282,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F6 · ownership.nature: The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionCommon Stock | 410,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 3 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 410,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F5 · ownership.nature: The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionCommon Stock | 193,742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 2 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 193,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.. F4 · ownership.nature: The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 17:01 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | ConversionCommon Stock | 1,614,515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-004404 · doc4.xml · nonDerivative · entry 1 Jovan-Embiricos Morana · CIK 0001575745 · Director · 10% owner Globeways Holdings Ltd · CIK 0001600769 · 10% owner Globeways Holdings II Ltd · CIK 0001768161 · 10% owner F2 Capital I 2015 Ltd · CIK 0001767391 · 10% owner F2 Bioscience II 2017 Ltd · CIK 0001767388 · 10% owner F2 Captial I 2017 Ltd · CIK 0001767390 · 10% owner F2 MG Ltd · CIK 0001767396 · 10% owner F2 - TPO Investments LLC · CIK 0001767397 · 10% owner F2 BBG LLC · CIK 0001767415 · 10% owner F2 Capital I 2019, LLC · CIK 0001767418 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Fund Disclosed balance after: 1,614,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.